187 related articles for article (PubMed ID: 2401166)
81. Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
Urbanitz D; Büchner T; Pielken H; Koch P; Ludwig WD; Maschmeier G; Heinecke A; van de Loo J
Haematol Blood Transfus; 1987; 30():64-8. PubMed ID: 3305224
[TBL] [Abstract][Full Text] [Related]
82. Pharmacokinetic study of cytosine arabinoside in patients with acute myelogeneous leukemia.
Preusser P; Pielken HJ; Bauch HJ
Haematol Blood Transfus; 1987; 30():288-92. PubMed ID: 3476359
[No Abstract] [Full Text] [Related]
83. The epipodophyllotoxin VP16-213 in combination chemotherapy for adults with acute nonlymphoblastic leukaemia.
Jacobs P
Haematol Blood Transfus; 1985; 29():70-4. PubMed ID: 3896977
[TBL] [Abstract][Full Text] [Related]
84. High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults.
Glucksberg H; Cheever MA; Farewell VT; Fefer A; Sale GE; Thomas ED
Cancer; 1981 Sep; 48(5):1073-81. PubMed ID: 7023650
[TBL] [Abstract][Full Text] [Related]
85. Treatment of acute nonlymphocytic leukemia in young and elderly patients.
Beguin Y; Bury J; Fillet G; Lennes G
Cancer; 1985 Dec; 56(11):2587-92. PubMed ID: 4052936
[TBL] [Abstract][Full Text] [Related]
86. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome.
Gajewski JL; Ho WG; Nimer SD; Hirji KF; Gekelman L; Jacobs AD; Champlin RE
J Clin Oncol; 1989 Nov; 7(11):1637-45. PubMed ID: 2809680
[TBL] [Abstract][Full Text] [Related]
87. Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years.
Bandini G; Zuffa E; Rosti G; Battista R; D'Emilio E; Leoni F; Ciolli S; Barbui T; Bassan R; Todeschini G
Br J Haematol; 1991 Apr; 77(4):486-90. PubMed ID: 2025573
[TBL] [Abstract][Full Text] [Related]
88. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
Tang J; Liu Y; Chen J; Xue H; Pan C; Gu L
Int J Hematol; 2011 May; 93(5):610-617. PubMed ID: 21509439
[TBL] [Abstract][Full Text] [Related]
89. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
Omura GA; Vogler WR; Lefante J; Silberman H; Knospe W; Gordon D; Jarrell R
Cancer; 1982 Apr; 49(8):1530-6. PubMed ID: 7039813
[TBL] [Abstract][Full Text] [Related]
90. Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy?
Aul C; Schneider W
Haematol Blood Transfus; 1990; 33():382-6. PubMed ID: 2323646
[No Abstract] [Full Text] [Related]
91. Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia.
Peterson BA; Bloomfield CD; Bosl GJ; Gibbs G; Malloy M
Cancer; 1980 Aug; 46(4):663-8. PubMed ID: 7397631
[TBL] [Abstract][Full Text] [Related]
92. 13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia.
Arlin ZA; Mertelsmann R; Berman E; Gee T; Kurland E; Chaganti RS; Jhanwar SC; Moore MA; Clarkson BD
J Clin Oncol; 1985 Apr; 3(4):473-6. PubMed ID: 3856630
[TBL] [Abstract][Full Text] [Related]
93. Postremission chemotherapy in adult acute non-lymphoblastic leukaemia including intensive or non-intensive consolidation therapy.
Giordano M; Riccardi A; Girino M; Brugnatelli S; Scivetti P; Luoni R; Invernizzi R; Ascari E
Eur J Cancer; 1991; 27(4):437-41. PubMed ID: 1827717
[TBL] [Abstract][Full Text] [Related]
94. Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia.
Aul C; Heyll A
Haematol Blood Transfus; 1987; 30():356-60. PubMed ID: 3476367
[No Abstract] [Full Text] [Related]
95. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
Paul C; Liliemark J; Tidefelt U; Gahrton G; Peterson C
Ther Drug Monit; 1989; 11(2):140-8. PubMed ID: 2718219
[TBL] [Abstract][Full Text] [Related]
96. Non-cardiotoxic anthracycline regimens in the treatment of acute myeloblastic leukaemia.
Boughton BJ; Franklin IM; Apperley J; Knight D
Br J Haematol; 1984 Oct; 58(2):378-80. PubMed ID: 6591946
[No Abstract] [Full Text] [Related]
97. Treatment of acute myeloid leukaemia in children.
Paton CM; Ekert H; Waters KD; Matthews RN; Toogood IR
Aust N Z J Med; 1982 Apr; 12(2):143-6. PubMed ID: 6953955
[TBL] [Abstract][Full Text] [Related]
98. Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival.
Foon KA; Yale C; Clodfelter K; Gale RP
JAMA; 1980 Oct; 244(16):1806-7. PubMed ID: 6932517
[TBL] [Abstract][Full Text] [Related]
99. Improved prognosis of acute nonlymphocytic leukemia in children: results of the 12th-ANLL protocol of Tokyo Children's Cancer Study Group.
Bessho F; Kigasawa H; Tsuchida M; Tsukimoto I; Nakazawa S; Yamamoto M; Tsunematsu Y; Yamada K; Sugita K; Ohkawa Y
Acta Paediatr Jpn; 1991 Aug; 33(4):533-9. PubMed ID: 1792913
[TBL] [Abstract][Full Text] [Related]
100. Contributions of host- and disease-related attributes to the outcome of patients with acute myelogenous leukemia.
Curtis JE; Messner HA; Hasselback R; Elhakim TM; McCulloch EA
J Clin Oncol; 1984 Apr; 2(4):253-9. PubMed ID: 6368758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
